Mycobacterium Citations List: January 2023
Literature Citations
1. Discovery of Anti-tubercular Analogues of Bedaquiline with Modified A-, B- and C-Ring Subunits. Barbaro, L., G. Nagalingam, J.A. Triccas, L. Tan, N.P. West, D.L. Priebbenow, and J.B. Baell. ChemMedChem, 2023. 18(1): e202200533. PMID[36259365].
[PubMed]. TB_01_2023.
2. Assay Development and Inhibition of the Mt-DprE2 Essential Reductase from Mycobacterium tuberculosis. Batt, S.M., S. Toth, B. Rodriguez, K.A. Abrahams, N. Veerapen, G. Chiodarelli, L.R. Cox, P.J. Moynihan, J. Lelievre, K. Fütterer, and G.S. Besra. Microbiology, 2023. 169(1). PMID[36748627].
[PubMed]. TB_01_2023.
3. Improving the Antimycobacterial Drug Clofazimine through Formation of Organic Salts by Combination with Fluoroquinolones. Bento, C.M., A.T. Silva, B. Mansano, L. Aguiar, C. Teixeira, M.S. Gomes, P. Gomes, T. Silva, and R. Ferraz. International Journal of Molecular Science, 2023. 24(2): 1402. PMID[36674923]. PMCID[PMC9865903].
[PubMed]. TB_01_2023.
4. Structural Determinants of Indole-2-carboxamides: Identification of Lead Acetamides with Pan Antimycobacterial Activity. Bhattarai, P., P. Hegde, W. Li, P.K. Prathipati, C.M. Stevens, L. Yang, H. Zhou, A. Pandya, K. Cunningham, J. Grissom, M. Roman Sotelo, M. Sowards, L. Calisto, C.J. Destache, S. Rocha-Sanchez, J.C. Gumbart, H.I. Zgurskaya, M. Jackson, and E.J. North. Journal of Medicinal Chemistry, 2023. 66(1): p. 170-187. PMID[36563291].
[PubMed]. TB_01_2023.
5. Evaluation of Everolimus Activity against Mycobacterium tuberculosis Using in Vitro Models of Infection. Bianco, D.M., F. De Maio, G. Santarelli, I. Palucci, A. Salustri, G. Bianchetti, G. Maulucci, F. Citterio, M. Sanguinetti, E. Tamburrini, M. Sali, and G. Delogu. Antibiotics, 2023. 12(1): 171. PMID[36671372]. PMCID[PMC9854797].
[PubMed]. TB_01_2023.
6. Hybridization Approach toward Novel Antituberculars: Design, Synthesis, and Biological Evaluation of Compounds Combining Pyrazinamide and 4-Aminosalicylic acid. Bouz, G., P. Šlechta, O. Jand'ourek, K. Konečná, P. Paterová, P. Bárta, M. Novák, R. Kučera, N.K. Dal, F. Fenaroli, J. Zemanová, M. Forbak, J. Korduláková, O. Pavliš, P. Kubíčková, M. Doležal, and J. Zitko. ACS Infectious Diseases, 2023. 9(1): p. 79-96. PMID[36577009].
[PubMed]. TB_01_2023.
7. Cyclic AMP-mediated Inhibition of Cholesterol Catabolism in Mycobacterium tuberculosis by the Novel Drug Candidate GSK2556286. Brown, K.L., K.M. Wilburn, C.R. Montague, J.C. Grigg, O. Sanz, E. Perez-Herran, D. Barros, L. Ballell, B.C. VanderVen, and L.D. Eltis. Antimicrobial Agents and Chemotherapy, 2023. 67(1): e0129422. PMID[36602336]. PMCID[PMC9872607].
[PubMed]. TB_01_2023.
8. In Silico Design and Investigation of Novel Thiazetidine Derivatives as Potent Inhibitors of PrpR in Mycobacterium tuberculosis. Dasmahapatra, U., S. Rajasekhar, G. Neelima, B. Maiti, R. Karuppasamy, P. Murali, B. Mm, and K. Chanda. Chemistry & Biodiversity, 2023. 20(1): e202200925. PMID[36519809].
[PubMed]. TB_01_2023.
9. Antimicrobial Effect of Oxazolidinones and Its Synergistic Effect with Bedaquiline against Mycobacterium abscessus Complex. Gao, T., C. Yao, Y. Shang, R. Su, X. Zhang, W. Ren, S. Li, W. Shu, Y. Pang, and Q. Li. Infection and Drug Resistance, 2023. 16: p. 279-287. PMID[36683910]. PMCID[PMC9850832].
[PubMed]. TB_01_2023.
10. Expanding the Knowledge around Antitubercular 5-(2-Aminothiazol-4-yl)isoxazole-3-carboxamides: Hit-to-lead Optimization and Release of a Novel Antitubercular Chemotype via Scaffold Derivatization. Girardini, M., F. Ferlenghi, G. Annunziato, G. Degiacomi, B. Papotti, C. Marchi, J.C. Sammartino, S.S. Rasheed, A. Contini, M.R. Pasca, F. Vacondio, J.C. Evans, T. Dick, R. Müller, G. Costantino, and M. Pieroni. European Journal of Medicinal Chemistry, 2023. 245(Pt 2): 114916. PMID[36399878].
[PubMed]. TB_01_2023.
11. Novel Quinoline-piperazine Hybrids: The Design, Synthesis and Evaluation of Antibacterial and Antituberculosis Properties. Gnanavelu, K., S.V. K, S. Eswaran, and K. Sivashanmugam. RSC Medicinal Chemistry, 2023. 14(1): p. 183-189. PMID[36760744]. PMCID[PMC9890665].
[PubMed]. TB_01_2023.
12. Molecular Characterization of Resistance to Second-line Anti-mycobacterial Drugs among Clinical Isolates of Multidrug-resistant Mycobacterium tuberculosis. Habibnia, S., M. Karami-Zarandi, S. Zaker, Z. Ghalavand, F. Doustdar, G. Eslami, and H. Kazemian. Clinical Laboratory, 2023. 69(1). PMID[36649505].
[PubMed]. TB_01_2023.
13. Iterative Methylation Leads to 3-Methylchuangxinmycin Production in Actinoplanes tsinanensis CPCC 200056. Hu, X., Y. Shi, B. Jiang, J. Fu, X. Li, S. Li, G. Sun, W. Ren, X. Hu, X. You, Z. Liu, X. Han, T. Zhang, B. Hong, and L. Wu. Journal of Natural Products, 2023. 86(1): p. 1-7. PMID[36649560].
[PubMed]. TB_01_2023.
14. Identification of 2-Aryl-quinolone Inhibitors of Cytochrome bd and Chemical Validation of Combination Strategies for Respiratory Inhibitors against Mycobacterium tuberculosis. Jeffreys, L.N., A. Ardrey, T.A. Hafiz, L.A. Dyer, A.J. Warman, N. Mosallam, G.L. Nixon, N.E. Fisher, W.D. Hong, S.C. Leung, G. Aljayyoussi, J. Bibby, D.V. Almeida, P.J. Converse, N. Fotouhi, N.G. Berry, E.L. Nuermberger, A.M. Upton, P.M. O'Neill, S.A. Ward, and G.A. Biagini. ACS Infectious Diseases, 2023. 9(2): p. 221-238. PMID[36606559].
[PubMed]. TB_01_2023.
15. Design, Synthesis and Biological Evaluation of Alkynyl-containing Maleimide Derivatives for the Treatment of Drug-resistant Tuberculosis. Li, P., B. Wang, X. Chen, Z.Y. Lin, G. Li, Y. Lu, and H.H. Huang. Bioorganic Chemistry, 2023. 131: 106250. PMID[36423487].
[PubMed]. TB_01_2023.
16. Bacillibactin Class Siderophores Produced by the Endophyte Bacillus subtilis Nproot3 as Antimycobacterial Agents. Nalli, Y., S. Singh, A. Gajjar, B. Mahizhaveni, V.N.A. Dusthackeer, and P.B. Shinde. Letters in Applied Microbiology, 2022. 2022: ovac026. ISI[000901596200001].
[WOS]. TB_01_2023.
17. Silver Nanoparticles as a Nanoprobe for Trace Level Simultaneous Detection of Streptomycin Sulfate and Isoniazid and anti-TB Activity of Their Nanoparticles Complexes. Naqvi, S.S., H. Anwar, M.Y. Noori, A. Siddiqui, Z. Ali, M.R. Shah, and S.A. Ali. Journal of Molecular Structure, 2023. 1275: 134634. ISI[000904874400004].
[WOS]. TB_01_2023.
18. Microbiological Profile, Preclinical Pharmacokinetics and Efficacy of CRS0393, a Novel Antimycobacterial Agent Targeting MmpL3. Ochsner, U.A., M.A. De Groote, T.C. Jarvis, H. Liu, T. Youmans, T. Hoang, W. Ribble, J. Day, W. Li, C. Pearce, A. Walz, C.M. Panthi, B. Rimal, C.M. Stevens, H.I. Zgurskaya, M. Jackson, D. Ordway, M. Gonzalez-Juarrero, X. Sun, G. Lamichhane, and C. Mason. Tuberculosis, 2023. 138: 102288. PMID[36470124]. PMCID[PMC9892229].
[PubMed]. TB_01_2023.
19. Cysteamine/Cystamine Exert anti-Mycobacterium abscessus Activity Alone or in Combination with Amikacin. Palucci, I., A. Salustri, F. De Maio, M.D.C. Pereyra Boza, F. Paglione, M. Sali, L. Occhigrossi, M. D'Eletto, F. Rossin, D. Goletti, M. Sanguinetti, M. Piacentini, and G. Delogu. International Journal of Molecular Science, 2023. 24(2): 1203. PMID[36674717]. PMCID[PMC9866335].
[PubMed]. TB_01_2023.
20. Nonhydrolyzable D‑Phenylalanine-benzoxazole Derivatives Retain Antitubercular Activity. Pepi, M.J., S. Chacko, N. Kopetz, H.I.M. Boshoff, G.D. Cuny, and L. Hedstrom. Bioorganic & Medicinal Chemistry Letters, 2023. 80: 129116. PMID[36572353]. PMCID[PMC9885953].
[PubMed]. TB_01_2023.
21. Synthesis and Antimycobacterial Activity of Isoniazid Derivatives Tethered with Aliphatic Amines. Pflegr, V., J. Stolarikova, J. Vinsova, and M. Kratky. Current Topics in Medicinal Chemistry, 2022. 22(32): p. 2695-2706. PMID[35929626].
[PubMed]. TB_01_2023.
22. Synthesis and Bio-evaluation of GR135486X Derivatives as Potent Anti-tubercular Agents. Sangu, K.G., S.D. Varakala, E.V. Krishna, A. Akhir, D. Saxena, M.N. Ahmad, S. Chopra, S. Misra, D. Sriram, and H.B. Rode. ChemistrySelect, 2023. 8(1): e202204186. ISI[000906030900001].
[WOS]. TB_01_2023.
23. Doxycycline as a Potential MMP-1 Inhibitor for the Treatment of Spondylitis Tuberculosis: A Study in Rabbit Model. Siregar, O., A. Lelo, A.J. Rahyussalim, S. Ilyas, Benny, T. Kurniawati, Y. Augustinus, Hendra, T. Mandagi, M.L.L. Zufar, and I. Fathurrahman. Biomedical Research International, 2023. 2023: 7421325. PMID[36743515]. PMCID[PMC9897918].
[PubMed]. TB_01_2023.
24. Synthetic Modifications of Abietane diterpene acids to Potent Antimicrobial Agents. Smirnova, I.E., E.V. Tret'yakova, D.S. Baev, and O.B. Kazakova. Natural Product Research, 2023. 37(2): p. 313-321. PMID[34448419].
[PubMed]. TB_01_2023.
25. Synthesis and Testing of Analogs of the Tuberculosis Drug Candidate SQ109 against Bacteria and Protozoa: Identification of Lead Compounds against Mycobacterium abscessus and Malaria Parasites. Stampolaki, M., S.R. Malwal, N. Alvarez-Cabrera, Z. Gao, M. Moniruzzaman, S.O. Babii, N. Naziris, A. Rey-Cibati, M. Valladares-Delgado, A.L. Turcu, K.H. Baek, T.N. Phan, H. Lee, M. Alcaraz, S. Watson, M. van der Watt, D. Coertzen, N. Efstathiou, M. Chountoulesi, C.M. Shoen, I.P. Papanastasiou, J. Brea, M.H. Cynamon, L.M. Birkholtz, L. Kremer, J.H. No, S. Vázquez, G. Benaim, C. Demetzos, H.I. Zgurskaya, T. Dick, E. Oldfield, and A.D. Kolocouris. ACS Infectious Diseases, 2023. 9(2): p. 342-364. PMID[36706233].
[PubMed]. TB_01_2023.
26. Production, Characterization, and Application of Phage-derived PK34 Recombinant Anti-microbial Peptide. Wang, J., T. Yuan, X. He, Z. Yi, H. Li, W. Gao, and Q. Li. Applied Microbiology and Biotechnology, 2023. 107(1): p. 163-174. PMID[36445388].
[PubMed]. TB_01_2023.
27. In Vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) against Tuberculosis. Xiao, H., X. Yu, Y. Shang, R. Ren, Y. Xue, L. Dong, L. Zhao, G. Jiang, and H. Huang. Infection and Drug Resistance, 2023. 16: p. 217-224. PMID[36647451]. PMCID[PMC9840375].
[PubMed]. TB_01_2023.
28. Discovery of 1-Hydroxy-2-methylquinolin-4(1H)-one Derivatives as New Cytochrome bd Oxidase Inhibitors for Tuberculosis Therapy. Zhou, Y., M. Shao, W. Wang, C.Y. Cheung, Y. Wu, H. Yu, X. Hu, G.M. Cook, H. Gong, and X. Lu. European Journal of Medicinal Chemistry, 2023. 245(Pt 1): 114896. PMID[36370551].
[PubMed]. TB_01_2023.
29. Synthesis and Structure-Activity Relationship of 2,6-Disubstituted thiosemicarbazone Derivatives of Pyridine as Potential Antituberculosis Agents. Ziembicka, D., K. Gobis, M. Szczesio, A. Olczak, E. Augustynowicz-Kopeć, A. Głogowska, I. Korona-Głowniak, and K. Bojanowski. Materials, 2023. 16(1): 448. PMID[36614785]. PMCID[PMC9822072].
[PubMed]. TB_01_2023.
Patent Citations
30. Piperazine Compounds for Modulating Mycobacterium tuberculosis Response and Their Preparation. Tan, S., J.S. Patel, J.S. Freudlich, A. Shelke, S. Daher, and M. Sherwood. Patent. 2023. WO2022-US73519 2023283608: 100 pages.
[Patent]. TB_01_2023.